Evaluation of different heterologous-homologous vaccine regimens against challenge with GI-23 lineage infectious bronchitis virus

IF 2.4 3区 医学 Q3 VIROLOGY Virology Pub Date : 2024-10-01 Epub Date: 2024-07-31 DOI:10.1016/j.virol.2024.110193
Mohamed H. Houta , Kareem E. Hassan , Walid H. Kilany , Salama A.S. Shany , Azza A. El-Sawah , Magdy F. ElKady , Ahmed S. Abdel-Moneim , Ahmed Ali
{"title":"Evaluation of different heterologous-homologous vaccine regimens against challenge with GI-23 lineage infectious bronchitis virus","authors":"Mohamed H. Houta ,&nbsp;Kareem E. Hassan ,&nbsp;Walid H. Kilany ,&nbsp;Salama A.S. Shany ,&nbsp;Azza A. El-Sawah ,&nbsp;Magdy F. ElKady ,&nbsp;Ahmed S. Abdel-Moneim ,&nbsp;Ahmed Ali","doi":"10.1016/j.virol.2024.110193","DOIUrl":null,"url":null,"abstract":"<div><p>This study assesses different IBV vaccination regimens in broiler chickens using commercially available live attenuated GI-23 (Egyptian-VAR2) and GI-1 (H120) vaccines. Vaccines were administered at 1, 14 days of age, or both. The ciliostasis test, following wild-type VAR2 challenge at 28 days of age, indicated that classic H120+VAR2 at one day old followed by the VAR2 vaccine at 14 days of age provided the highest level of protection (89.58%). Similarly, administering VAR2 at 1 day of age and classic H120 at 14 days of age demonstrated substantial protection (85.42%). Conversely, administering only classic H120 and VAR2 at one day old resulted in the lowest protection level (54.17%). Tracheal virus shedding quantification and assessment of trachea and kidney degenerative changes were significantly lower in vaccinated groups compared to the unvaccinated-challenged group. In conclusion, a carefully planned vaccination regimen based on homologous vaccination offers the most effective clinical protection in broiler chickens.</p></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"598 ","pages":"Article 110193"},"PeriodicalIF":2.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682224002149","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study assesses different IBV vaccination regimens in broiler chickens using commercially available live attenuated GI-23 (Egyptian-VAR2) and GI-1 (H120) vaccines. Vaccines were administered at 1, 14 days of age, or both. The ciliostasis test, following wild-type VAR2 challenge at 28 days of age, indicated that classic H120+VAR2 at one day old followed by the VAR2 vaccine at 14 days of age provided the highest level of protection (89.58%). Similarly, administering VAR2 at 1 day of age and classic H120 at 14 days of age demonstrated substantial protection (85.42%). Conversely, administering only classic H120 and VAR2 at one day old resulted in the lowest protection level (54.17%). Tracheal virus shedding quantification and assessment of trachea and kidney degenerative changes were significantly lower in vaccinated groups compared to the unvaccinated-challenged group. In conclusion, a carefully planned vaccination regimen based on homologous vaccination offers the most effective clinical protection in broiler chickens.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对 GI-23 系传染性支气管炎病毒挑战的不同异源同种疫苗方案评估
本研究评估了使用市售 GI-23(埃及-VAR2)和 GI-1(H120)减毒活疫苗接种肉鸡的不同 IBV 疫苗方案。疫苗分别在 1 日龄、14 日龄接种,或同时接种两种疫苗。在 28 日龄接种野生型 VAR2 后进行的纤溶试验表明,在 1 日龄接种传统的 H120+VAR2 疫苗,然后在 14 日龄接种 VAR2 疫苗可提供最高水平的保护(89.58%)。同样,1日龄时接种VAR2疫苗,14日龄时接种经典H120疫苗,也能提供相当高的保护率(85.42%)。相反,仅在 1 日龄时注射经典 H120 和 VAR2 的保护率最低(54.17%)。与未接种疫苗的挑战组相比,接种疫苗组的气管病毒脱落定量以及气管和肾脏退行性变化评估结果均显著降低。总之,基于同源疫苗接种的精心策划的疫苗接种方案可为肉鸡提供最有效的临床保护。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Virology
Virology 医学-病毒学
CiteScore
6.00
自引率
0.00%
发文量
157
审稿时长
50 days
期刊介绍: Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.
期刊最新文献
Genomic characterization of a novel human astrovirus MLB1 variant from Tanzania The influence of natural adaptation of the DCS-PK structure on the replication efficiency of Zika virus Characterization of bacteriophage Henu4_2 lytic for Escherichia coli and its therapeutic efficacy in infection models Role of LSDV ORF102 in immune evasion and characterization of ORF102-Deleted recombinant virus Machine learning framework for early detection of polio outbreaks from acute flaccid paralysis surveillance data
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1